Ethan W. Hollingsworth

Ethan W. Hollingsworth

Auto-generated profile, based on publicly available information

Ethan W. Hollingsworth

Department of Developmental and Cell Biology, University of California Irvine, Irvine, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2022 in Science
Verified
Journal Article
Closed access
CYConnor Yanchus
Connor Yanchus
KDKristen L. Drucker
Kristen L. Drucker
TKThomas M. Kollmeyer
Thomas M. Kollmeyer
RTRicky Tsai
Ricky Tsai
WWWarren Winick-Ng
Warren Winick-Ng
DSDaniel Schramek
Daniel Schramek
Establishing causal links between inherited polymorphisms and cancer risk is challenging. Here, we focus on the single-nucleotide polymorphism rs55705857, which confers a sixfold greater risk of isocitrate dehydrogenase ( IDH) –mutant low-grade glioma (LGG). We reveal that rs55705857 itself is the causal variant and is associated with molecular pathways that drive LGG. Mechanistically, we show that rs55705857 resides within a brain-specific enhancer, where the risk allele disrupts OCT2/4 binding, allowing increased interaction with the Myc promoter and increased Myc expression. Mutating the orthologous mouse rs55705857 locus accelerated tumor development in an Idh1 R132H -driven LGG mouse model from 472 to 172 days and increased penetrance from 30% to 75%. Our work reveals mechanisms of the heritable predisposition to lethal glioma in ~40% of LGG patients.

27 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
GBGrace Bower
Grace Bower
EHEthan W. Hollingsworth
Ethan W. Hollingsworth
SJSandra Jacinto
Sandra Jacinto
BCBenjamin Clock
Benjamin Clock
KCKaitlyn Cao
Kaitlyn Cao
EKEvgeny Z. Kvon
Evgeny Z. Kvon
While most mammalian enhancers regulate their cognate promoters over moderate distances of tens of kilobases (kb), some enhancers act over distances in the megabase range. The sequence features enabling such extreme-distance enhancer-promoter interactions remain elusive. Here, we used in vivo enhancer replacement experiments in mice to show that short– and medium-range enhancers cannot initiate gene expression at extreme-distance range. We uncover a novel conserved cis -acting element, R ange EX tender (REX), that confers extreme-distance regulatory activity and is located next to a long-range enhancer of Sall1 . The REX element itself has no endogenous enhancer activity. However, addition of the REX to other short– and mid-range enhancers substantially increases their genomic interaction range. In the most extreme example observed, addition of the REX increased the range of an enhancer by an order of magnitude, from its native 71kb to 840kb. The REX element contains highly conserved [C/T]AATTA homeodomain motifs. These motifs are enriched around long-range limb enhancers genome-wide, including the ZRS, a benchmark long-range limb enhancer of Shh . Mutating the [C/T]AATTA motifs within the ZRS does not affect its limb-specific enhancer activity at short range, but selectively abolishes its long-range activity, resulting in severe limb reduction in knock-in mice. In summary, we identify a sequence signature globally associated with long-range enhancer-promoter interactions and describe a prototypical REX element that is necessary and sufficient to confer extreme-distance gene activation by remote enhancers.

6 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
EHEthan W. Hollingsworth
Ethan W. Hollingsworth
TLTaryn Audrey Liu
Taryn Audrey Liu
JAJoshua A. Alcantara
Joshua A. Alcantara
CCCindy X. Chen
Cindy X. Chen
SJSandra H. Jacinto
Sandra H. Jacinto
EKEvgeny Z. Kvon
Evgeny Z. Kvon
Functional analysis of non-coding variants associated with congenital disorders remains challenging due to the lack of efficient in vivo models. Here we introduce dual-enSERT, a robust Cas9-based two-color fluorescent reporter system which enables rapid, quantitative comparison of enhancer allele activities in live mice in less than two weeks. We use this technology to examine and measure the gain- and loss-of-function effects of enhancer variants previously linked to limb polydactyly, autism spectrum disorder, and craniofacial malformation. By combining dual-enSERT with single-cell transcriptomics, we characterise gene expression in cells where the enhancer is normally and ectopically active, revealing candidate pathways that may lead to enhancer misregulation. Finally, we demonstrate the widespread utility of dual-enSERT by testing the effects of fifteen previously uncharacterised rare and common non-coding variants linked to neurodevelopmental disorders. In doing so we identify variants that reproducibly alter the in vivo activity of OTX2 and MIR9-2 brain enhancers, implicating them in autism. Dual-enSERT thus allows researchers to go from identifying candidate enhancer variants to analysis of comparative enhancer activity in live embryos in under two weeks.

9 October 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
FWFumihiro Watanabe
Fumihiro Watanabe
EHEthan W. Hollingsworth
Ethan W. Hollingsworth
JBJenna M. Bartley
Jenna M. Bartley
LWLauren Wisehart
Lauren Wisehart
RDRahil Desai
Rahil Desai
JIJaime Imitola
Jaime Imitola
Summary: Glioblastoma stem cells (GSCs) are highly self-renewing, resistant to therapy, and are able to form lethal tumors 1, 2 . Tumor organoids have been developed to study tumor evolution 1–4 , and while GSCs can form organoids for glioblastoma multiforme, our understanding of their intrinsic immune, metabolic, genetic, and molecular programs is limited. To address this, we deeply characterized GSC-derived GBM organoids using a modified protocol (GBMOsm) from several patient-derived GSCs and found they develop into complex 3D tissues with unique self-organization, cancerous metabolic states, and burdensome genetic landscapes. We discovered that GBMOsc recapitulate the presence of two important cell populations thought to drive GBM progression, SATB2 + and HOPX + progenitors. Despite being devoid of immune cells, transcriptomic analysis across GBMOsc revealed an immune-like molecular program, enriched in cytokine, antigen presentation and processing, T-cell receptor inhibitors, and interferon genes. We determined that SATB2 + and HOPX + populations contribute to this immune and interferon landscape in GBM in vivo and GBMOsm. Our work deepens our understanding of the intrinsic molecular and cellular architecture of GSC-derived GBMO and defines a novel GBMOsc intrinsic immune-like program.

10 December 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
EHEthan W. Hollingsworth
Ethan W. Hollingsworth
TLTaryn A. Liu
Taryn A. Liu
SJSandra H. Jacinto
Sandra H. Jacinto
CCCindy X. Chen
Cindy X. Chen
JAJoshua A. Alcantara
Joshua A. Alcantara
EKEvgeny Z. Kvon
Evgeny Z. Kvon
Functional analysis of non-coding variants associated with human congenital disorders remains challenging due to the lack of efficient in vivo models. Here we introduce dual-enSERT, a robust Cas9-based two-color fluorescent reporter system which enables rapid, quantitative comparison of enhancer allele activities in live mice of any genetic background. We use this new technology to examine and measure the gain- and loss-of-function effects of enhancer variants linked to limb polydactyly, autism, and craniofacial malformation. By combining dual-enSERT with single-cell transcriptomics, we characterize variant enhancer alleles at cellular resolution, thereby implicating candidate molecular pathways in pathogenic enhancer misregulation. We further show that independent, polydactyly-linked enhancer variants lead to ectopic expression in the same cell populations, indicating shared genetic mechanisms underlying non-coding variant pathogenesis. Finally, we streamline dual-enSERT for analysis in F0 animals by placing both reporters on the same transgene separated by a synthetic insulator. Dual-enSERT allows researchers to go from identifying candidate enhancer variants to analysis of comparative enhancer activity in live embryos in under two weeks.

19 March 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
FWFumihiro Watanabe
Fumihiro Watanabe
EHEthan W. Hollingsworth
Ethan W. Hollingsworth
YBYeshavanth Banasavadi-Siddegowda
Yeshavanth Banasavadi-Siddegowda
JBJenna M. Bartley
Jenna M. Bartley
SSSteven T. Sizemore
Steven T. Sizemore
JIJaime Imitola
Jaime Imitola
The intrinsic genetic program of glioblastoma (GBM) stem cells is critical for tumor evolution and recurrence. We recently identified intrinsic phenotypes and immune-like genetic programs of GBM organoids (GBMO) 1 from patient derived glioblastoma stem cells (GSCs), replicating genomic, metabolic, and cellular aspects of GBM in vivo . Aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor, is a key regulator of infiltrating immune cells in gliomas 2, 3 and associated with poor prognosis, but its role in GSC biology is unknown 2 . Here, we show that AHR is a patient-specific regulator of the glioma intrinsic gene program in GSCs and GSC-derived GBMO that are enriched for AHR. We find that AHR is required for GSC self-renewal, GBMO expansion, radial glia-like cell proliferation, and expression of immune mediators seen in the mesenchymal subtype. CRISPR-Cas9 genetic ablation and pharmacological inhibition revealed that AHR regulates genes linked to intrinsic immunity, proliferation, and migration in GBMO. Genomic analysis of GBMO treated with AHR inhibitors identified expression signatures and candidate markers associated with survival of gliomas. Our work defines the glioma intrinsic function of AHR in a model of early GBM formation, offering a rationale for clinical exploration of a potential ‘two-hit’ target of both GBM cells and infiltrating immune cells in patients with GBM expressing high levels of AHR.